Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy

Grants

Funding Acknowledgements

J.S.: advisory boards of Roche, Gilead Sciences; grants: Roche, Gilead Sciences; honoraria: Roche, Gilead Sciences, Bristol Myers Squibb; travel/accommodation: Roche, Gilead Sciences, Schering-Plough Pty. Ltd. G. D.: advisory boards: Roche, Gilead Sciences, Abbott Pharmaceuticals, Merck Sharp and Dohme and Novartis, Bristol Myers Squibb; grants: Roche, Gilead Sciences; honoraria: Roche, Gilead Sciences, Merck Sharp and Dohme and Janssen-Cilag; travel/accommodation: Roche, ScheringPlough Pty. Ltd. I. K.: none. D. B.: none. M.Y.: employee and shareholder of Roche. M. W.: advisory boards: Roche, Novartis and Janssen-Cilag; honoraria: Roche.Study coordinators: Maxine Giourouki, Joanne Patterson, Vincent Fragomelli, Brigita Gregorevic, Marion Croft and Zoe Potgeister. National Centre in HIV Epidemiology and Clinical Research is funded by the Department of Health and Ageing. G. D. is funded by a NHMRC Practitioner Fellowship. The authors thank Roche Products Pty. Ltd, especially Deborah Richards and Dr Scott Bowden, Victorian Infectious Diseases Reference Laboratory for virology support.